Although many women initially quit smoking during pregnancy, most will return to smoking by the end of pregnancy or during the first 6 months postpartum. The proposed pilot project is designed to evaluate the feasibility and potential efficacy of offering small financial incentives for the completion of smoking cessation coaching and biochemically-verified smoking abstinence at follow-up among pregnant women with Medicaid insurance who contact the Oklahoma Tobacco Helpline (OTH). The study will enroll 100 pregnant women who will be randomly assigned to OTH care or OTH plus escalating incentives (OTH+I) for completing up to 5 coaching calls over the first 8 weeks after enrolling (prepartum) and for biochemically-verified smoking abstinence at 9 weeks post-enrollment (assessed remotely via smartphone). In addition, participants will be incentivized for completing a postpartum coaching call by 8 weeks postpartum. Feasibility outcomes for the incentives based intervention will focus on coaching call completion, rates of prepartum and postpartum follow-up, biochemically-verified smoking cessation, and perceptions of the intervention. Potential effectiveness will be evaluated by comparing biochemically-verified smoking abstinence rates in OTH+I relative to OTH alone at 12 weeks post-enrollment (prepartum) and 12 weeks postpartum.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
TSET Health Promotion Research Center
Oklahoma City, Oklahoma, United States
Biochemically verified abstinence 12 weeks post enrollment
The outcome measure is biochemically verified over 7-day point prevalence at 12 weeks post-enrollment.
Time frame: 12 weeks post enrollment
Self-reported abstinence 12 weeks postpartum
The outcome measure is biochemically verified abstinence over 7-day point prevalence at 12 weeks post-partum
Time frame: 12 weeks postpartum
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.